Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
Crossref DOI link: https://doi.org/10.1007/s00432-017-2365-y
Published Online: 2017-03-04
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Niinivirta, Marjut
Enblad, Gunilla
Edqvist, Per-Henrik
Pontén, Fredrik
Dragomir, Anca
Ullenhag, Gustav J.
License valid from 2017-03-04